Invention Grant
- Patent Title: Pyrrolo[2,3-d]pyrimidine compound or salt thereof
-
Application No.: US15746208Application Date: 2016-07-29
-
Publication No.: US10421760B2Publication Date: 2019-09-24
- Inventor: Masayuki Nakamura , Hiroyoshi Yamanaka , Morihiro Mitsuya , Takafumi Harada
- Applicant: TAIHO PHARMACEUTICAL CO., LTD.
- Applicant Address: JP Chiyoda-ku
- Assignee: TAIHO PHARMACEUTICAL CO., LTD.
- Current Assignee: TAIHO PHARMACEUTICAL CO., LTD.
- Current Assignee Address: JP Chiyoda-ku
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Priority: JP2015-152123 20150731
- International Application: PCT/JP2016/072258 WO 20160729
- International Announcement: WO2017/022648 WO 20170209
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/519 ; A61P25/00 ; A61K47/32 ; C07D207/30 ; C07D307/34 ; A61P29/00
![Pyrrolo[2,3-d]pyrimidine compound or salt thereof](/abs-image/US/2019/09/24/US10421760B2/abs.jpg.150x150.jpg)
Abstract:
Provided are a novel compound or a salt thereof, and a pharmaceutical composition comprising the same, which selectively and strongly inhibit JAK3, exhibit an excellent activity for suppressing the growth of human peripheral blood monocytes and an excellent oral absorbability, and exhibits an activity of inhibiting IL-2-induced IFN-γ production in vivo. A compound represented by formula (I) [wherein X represents —CH═CH—, —NH—, a sulfur atom or an oxygen atom; and n represents an integer of 0 to 2], or a salt thereof.
Public/Granted literature
- US20180208598A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUND OR SALT THEREOF Public/Granted day:2018-07-26
Information query